Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 500
- Registration Number
- NCT00001084
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States
🇺🇸Stanford Univ Med Ctr, Stanford, California, United States
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 56
- Registration Number
- NCT00000725
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 30
- Registration Number
- NCT00000753
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001063
- Locations
- 🇺🇸
Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 750
- Registration Number
- NCT00000671
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 116
- Registration Number
- NCT00000656
- Locations
- 🇺🇸
Univ of Washington, Seattle, Washington, United States
🇺🇸Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California, United States
🇺🇸Whitman - Walker Clinic, Washington, District of Columbia, United States
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000887
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States
🇺🇸Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 210
- Registration Number
- NCT00000791
- Locations
- 🇺🇸
Washington U CRS, Saint Louis, Missouri, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Weiss Memorial Hosp., Chicago, Illinois, United States
A Study of Zidovudine in HIV-Infected Patients With Kidney Problems
- Conditions
- Locations
- 🇺🇸
Univ of Washington, Seattle, Washington, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00002033
- Locations
- 🇧🇷
Instituto Do Cancer Arnaldo Vieiro, Sao Paulo, Brazil
🇧🇷Escola Paulista De-Medicina, Sao Paulo, Brazil
🇧🇷Faculdade De-Ciencias Medica Da, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.